Clinical TrialMay 18, 2026, 08:32 AM
Silexion gets Israeli approval, submits German CTA for SIL204 Phase 2/3 trial
AI Summary
Silexion Therapeutics announced significant progress in its clinical development, receiving Israeli Ministry of Health approval and submitting a Clinical Trial Application to Germany for its Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer, with trial initiation expected in Q2 2026. Financially, the company reported increased R&D and G&A expenses, leading to a net loss of $2.7 million in Q1 2026. However, subsequent to quarter-end, Silexion strengthened its balance sheet through a warrant exercise and ATM facility, restoring compliance with Nasdaq listing requirements.
Key Highlights
- Israeli Ministry of Health approved initiation of Silexion's Phase 2/3 clinical trial of SIL204.
- Clinical Trial Application (CTA) for SIL204 Phase 2/3 trial submitted to Germany.
- Phase 2/3 clinical trial initiation remains on track for the second quarter of 2026.
- Research and development expenses increased 133.3% to $1.4 million in Q1 2026.
- Net loss for Q1 2026 increased 58.8% to $2.7 million.
- Cash and cash equivalents were $2.4 million as of March 31, 2026.
- Subsequent warrant exercise generated approximately $1.0 million in gross proceeds.
- Shareholders' equity raised above $2.5 million minimum for Nasdaq listing compliance.
Price Impact
More from SLXN